BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 6177765)

  • 1. Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies.
    Golan MD; Burger R; Loos M
    J Immunol; 1982 Aug; 129(2):445-7. PubMed ID: 6177765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q.
    Heinz HP; Burger R; Golan MD; Loos M
    J Immunol; 1984 Feb; 132(2):804-8. PubMed ID: 6606678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
    Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
    J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of C1q by monoclonal antibodies.
    Heinz HP; Loos M
    Behring Inst Mitt; 1984 Nov; (76):42-58. PubMed ID: 6335397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological functions of C1q expressed by conformational changes.
    Heinz HP
    Behring Inst Mitt; 1989 Jul; (84):20-31. PubMed ID: 2478117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
    Pearlstein E; Sorvillo J; Gigli I
    J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal anti-mouse macrophage antibodies recognize the globular portions of C1q, a subcomponent of the first component of complement.
    Heinz HP; Dlugonska H; Rüde E; Loos M
    J Immunol; 1984 Jul; 133(1):400-4. PubMed ID: 6609989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG pair formation on one antigenic molecule is the main mechanism of synergy between antibodies in complement-mediated lysis.
    Hughes-Jones NC; Gorick BD; Miller NG; Howard JC
    Eur J Immunol; 1984 Nov; 14(11):974-8. PubMed ID: 6209148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-independent activation of C1. I. Differences in the mechanism of C1 activation by nonimmune activators and by immune complexes: C1r-independent activation of C1s by cardiolipin vesicles.
    Kovacsovics TJ; Peitsch MC; Kress A; Isliker H
    J Immunol; 1987 Mar; 138(6):1864-70. PubMed ID: 3029222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune complex mediated activation of the classical complement pathway.
    Borsos T
    Behring Inst Mitt; 1989 Jul; (84):93-101. PubMed ID: 2478118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-induced immune complex disease: genetic control of C1q binding complexes in the circulation of mice persistently infected with lymphocytic choriomeningitis virus.
    Oldstone MB; Tishon A; Buchmeier MJ
    J Immunol; 1983 Feb; 130(2):912-8. PubMed ID: 6217255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Requirements for the binding of human plasma fibronectin to the C1q subunit of the first component of complement.
    Sorvillo J; Gigli I; Pearlstein E
    J Immunol; 1983 Sep; 131(3):1400-4. PubMed ID: 6309962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of immune-complex size and antigen-antibody ratio on immune complex detection with monoclonal rheumatoid factor and C1q.
    Vanham G; Bloemmen FJ; Ceuppens JL; Stevens EA
    J Clin Lab Immunol; 1984 Oct; 15(2):63-8. PubMed ID: 6335179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays.
    Duquesnoy RJ; Marrari M; Jelenik L; Zeevi A; Claas FH; Mulder A
    Hum Immunol; 2013 Oct; 74(10):1271-9. PubMed ID: 23770250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surfactant protein A regulates complement activation.
    Watford WT; Wright JR; Hester CG; Jiang H; Frank MM
    J Immunol; 2001 Dec; 167(11):6593-600. PubMed ID: 11714829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C1 subcomponent complexes: basic and clinical aspects.
    Laurell AB; Sjöholm AG
    Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells.
    Bigler C; Schaller M; Perahud I; Osthoff M; Trendelenburg M
    J Immunol; 2009 Sep; 183(5):3512-21. PubMed ID: 19648280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible mechanisms of degradation of C1q in vivo and in vitro: role of macrophages.
    Daha MR
    Behring Inst Mitt; 1989 Jul; (84):42-6. PubMed ID: 2529843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of synergistic complement-mediated lysis of rat red cells by monoclonal IgG antibodies.
    Hughes-Jones NC; Gorick BD; Howard JC
    Eur J Immunol; 1983 Aug; 13(8):635-41. PubMed ID: 6603980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.